Companies › Sirnaomics
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Other; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| STP705 siRNA targeting TGF-β1 and COX-2 for inflammation and adipose tissue remodeling inhibition | TGFB1, PTGS2 | Phase 2 | Submental Fullness | Jul 2027 |
| FXI-GalNAc-siRNA Factor XI silencing RNA (GalNAc-conjugated siRNA) | F11 | Phase 1 | FXI | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05844293 | FXI-GalNAc-siRNA | Phase 1 | FXI | Other | May 2027 |
| NCT07677683 | STP705 | Phase 2 | Submental Fullness | Other | Jul 2027 |
Tortugas Neuroscience Mylan Pharmaceuticals Shanghai Argo Biopharmaceutical AFT Pharmaceuticals Healx
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.